MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting

Rhea-AI Summary

MorphoSys AG presented interim results from the M-PLACE study of felzartamab at the 2021 Annual Meeting of the American Society of Nephrology. This Phase 1b/2a study focuses on treating patients with anti-PLA2R positive membranous nephropathy, an autoimmune kidney disease. Of the 27 evaluable patients, 24 experienced rapid antibody titer reduction within a week, with some achieving substantial decreases after 12 weeks. Early signs of kidney function improvement were noted. The safety profile was consistent with expectations, indicating promising potential for felzartamab in this challenging patient population.

Positive

• 24 out of 27 patients showed rapid reduction in anti-PLA2R antibody levels after one week.
• Most patients experienced substantial reduction in antibody titer after 12 weeks.
• Early signs of improvement in kidney function were observed in several patients.

Negative

• None.

Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) presented interim results from the M-PLACE study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology (ASN) on November 4-7. The poster entitled "Felzartamab in patients with anti-phospholipase A2 receptor autoantibody positive (anti-PLA2R+) membranous nephropathy (MN): Interim results from the M-PLACE study" shows data from the ongoing Phase 1b/2a, proof of concept, open-label, multicenter study designed to assess the safety and efficacy of felzartamab in adults with high anti-PLA2R-positive MN, an autoimmune kidney disease and a leading cause of nephrotic syndrome in adults. Patients with high autoantibody titers are considered a population difficult to induce immunologic remission.

Felzartamab is an investigational, fully human IgG1 monoclonal anti-CD38 antibody that has a high potential to deplete CD38-positive plasma cells that produce and secrete these destructive autoantibodies. Depleting those plasma cells could be effective in the treatment of anti-PLA2R antibody-positive MN.

The M-PLACE study included 31 patients with primarily medium or high levels of anti-PLA2R antibody titers at baseline and/or patients who were refractory to previous treatments. Of the 27 treated patients with evaluable results, 24 showed an initial rapid reduction of anti-PLA2R antibody levels one week after the first treatment. After 12 weeks of treatment, most patients showed a substantial reduction in autoantibody titer. The observed titer reduction was independent of cohort and suggests successful depletion of CD38-positive plasma cells. Safety profile was consistent with the proposed mechanism of action of felzartamab and treatment-emergent adverse events were manageable. An early assessment of urine protein: creatinine ratio (UPCR) results at 6 months of treatment showed a decrease in 6 of 10 patients, with 4 patients having a decrease of >=50% from baseline. The first patient who has already reached the 12-month time point showed a complete immunologic response and a partial clinical response.

"These encouraging early data show that felzartamab has the potential to decrease autoantibodies responsible for the development and progression of membranous nephropathy," said Dr. Malte Peters, Chief Research and Development Officer, MorphoSys. "We are looking forward to generating more mature data to confirm how these findings translate into a clinical benefit for patients and the design for a potential pivotal study."

"Early proteinuria reduction was observed in several patients six months after felzartamab therapy was started," said Brad Rovin, MD nephrologist at Ohio State University and the lead author of the poster. "We are excited to see how proteinuria changed in response to felzartamab as follow-up data from the M-PLACE trial continue to accumulate."

More mature data from all patients will be obtained over the following months, including the complete urine protein: creatinine ratios (UPCR) for all patients, to evaluate if the observed immunological response is followed by a clinical response.

About Membranous Nephropathy (MN):
Primary membranous nephropathy (MN) is a rare autoimmune kidney disease and a leading cause of nephrotic syndrome in adults worldwide.^[1] MN has a global incidence of approximately 1.2/100,000 per year.^[2] As many as 40-50% of patients with MN progress to end-stage kidney disease (ESKD) within 5-15 years of diagnosis.^[3],[4] Even in the absence of ESKD, patients with long-term nephrotic syndrome are at risk of severe and life-threatening thromboembolic events and cardiovascular disease.³ Approximately 75% of primary MN cases arise due to autoantibodies to the phospholipase A2 receptor (PLA2R) that target PLA2R on podocytes^[5],[6]. The immune complexes formed by the binding of these autoantibodies to PLA2R induce complement activation and inflammation, which thickens the glomerular membrane and impairs kidney function¹.The main source of autoantibodies is CD38+/CD20- plasma cells and plasmabasts^[7]. Higher anti-PLA2R autoantibody titer is associated with more severe disease, a longer time to disease remission, and a decreased response to anti-CD20 rituximab treatment^5,[8],[9]. There are no approved therapies for MN, the current standard of care comprises off-label use of non-immunosuppressive agents (e.g. angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, statins, and diuretics)^1,[10], conventional immunosuppressive treatments (ISTs) (e.g. cyclophosphamide combined with steroids, calcineurin inhibitors, mycophenolate mofetil)^1,10 or B-cell depleting agents (e.g. anti-CD20 antibodies)^1,10. However, these treatments are not effective in all patients and, in particular, conventional ISTs are associated with a high risk of toxicity^1,5,10.

About Felzartamab
Felzartamab (MOR202/TJ202) is a therapeutic human monoclonal antibody derived from MorphoSys' HuCAL antibody library and directed against CD38. In Membranous Nephropathy, long-lived plasma cells drive pathogenic antibody production, contributing to functional damage to the glomeruli in the kidney. By targeting CD38, Felzartamab has the potential to deplete the CD38 positive plasma cells, which may ultimately improve patient's kidney functions.
MorphoSys is currently evaluating the safety and efficacy of investigational Felzartamab for patients with anti-PLA2R antibody-positive membranous nephropathy (M-PLACE and NewPLACE trial) and Immunoglobulin A Nephropathy (IGNAZ trial).

In 2017, MorphoSys entered into an exclusive regional licensing agreement with I-Mab Biopharma (NASDAQ:IMAB) to develop and commercialize Felzartamab in Greater China. I-Mab is currently conducting two parallel registrational trials with felzartamab as a third-line monotherapy and as a second-line combination therapy with lenalidomide, both in patients with multiple myeloma (MM) in Greater China. Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021 and the MM second line registrational trial is on track for completion of patient enrollment.

Felzartamab is an investigational drug that has not yet been approved by any regulatory authorities.

About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya^(R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi^(R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com.

Monjuvi^(R) and HuCAL^(R) are registered trademarks of MorphoSys AG.

Tremfya^(R) is a registered trademark of Janssen Biotech, Inc.

Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:

Media Contacts:
Thomas Biegi
Vice President
Tel: +49 (0)89 / 89927 26079
thomas.biegi@morphosys.com

Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com

Jeanette Bressi
Director, US Communications
Tel: +1 617-404-7816
jeanette.bressi@morphosys.com

Myles Clouston
Senior Director
Tel: +1 857-772-0240
myles.clouston@morphosys.com

^[1] Ronco P, et al. Nat Rev Dis Prim 2021;7(1):1-23.
^[2] McGrogan A, et al. Nephrol Dial Transplant 2011;26(2):414-30.
^[3] Passerini P, et al. Front Immunol 2019;10(JUN):1-9.
^[4] Lai WL, et al. J Formos Med Assoc 2015;114(2):102-11.
^[5] Bomback AS, et al. Am J Nephrol 2018;47(suppl 1):30-42.
^[6] Beck LH, et al. N Engl J Med 2009;361(1):11-21.
^[7] Hofmann K, et al. Front Immunol 2018;9:835-851.
^[8] Hoxha E, et al. J Am Soc Nephrol 2014;25(6):1357-66.
^[9] Bech AP, et al. Clin J Am Soc Nephrol 2014;9(8):1386-92.
^[10] Rovin BH, et al. Kidney Int 2021;100(4):S1-276.

SOURCE: MorphoSys AG

View source version on accesswire.com:
https://www.accesswire.com/671290/MorphoSys-Presents-Interim-Results-from-M-PLACE-Study-with-Felzartamab-during-American-Society-of-Nephrology-Annual-Meeting

FAQ

What are the interim results of the M-PLACE study for MOR?

The interim results show that 24 out of 27 treated patients experienced a rapid reduction in anti-PLA2R antibody levels after one week of treatment.

How does felzartamab work for treating membranous nephropathy?

Felzartamab targets CD38, helping to deplete plasma cells that produce anti-PLA2R antibodies, potentially improving kidney function.

What is the significance of the M-PLACE study results for MorphoSys (MOR)?

The results suggest that felzartamab could be an effective treatment for a difficult-to-treat autoimmune kidney disease, thus enhancing MorphoSys's drug development portfolio.

When were the interim results of the M-PLACE study presented?

The results were presented on November 4, 2021, during the Annual Meeting of the American Society of Nephrology.

What percentage of patients showed a reduction in nephrotic syndrome symptoms after felzartamab treatment?

Early assessments indicated that 6 out of 10 patients showed a decrease in proteinuria six months after starting felzartamab therapy.